Veige Healthcare

Coming – August 25

An OTC Treatment For 32 Million Women With VVA

Date and Time

August 25

–

12:00 PM ET 9:00 AM PT

Details will be provided upon RSVP approval

About this Event

Veige Healthcare is a biopharmaceutical company developing the first hormone-free, topical treatment for Vulvovaginal Atrophy (VVA). More than 32 million women in the U.S. suffer from VVA, a painful, under-addressed condition with only one approved treatment — Hormone Replacement Therapy. HRT requires a “Black Box” warning of serious risks like cardiac events, stroke, dementia, and cancer.

Veige Healthcare’s natural topical treatment has been clinically proven to reduce inflammation, penetrate tissue, and repair damage caused by VVA. It provides significant relief from itching, dryness, and pain, along with restored vaginal health, without the risks of estrogen-based therapies.

Veige is in the process of applying for 510(k) FDA clearance and is protected by an extensive patent portfolio covering its composition, use, and formulation. The product will be available over the counter and aims to launch direct-to-consumer in Q3 2026. They will expand to Amazon Marketplace and other online retail platforms before exploring options with traditional retailers like CVS and Target.

Join our Fireside Chat with Jonathan Kalman, CEO, Dr. William Levine, CSO, and Les Kraus, CFO of Veige Healthcare to learn why the U.S. market for VVA treatments is projected to reach $1.63B by 2032, with global growth expected to surpass $8.4B by 2036.

Sign Up Today

SHARE THIS EVENT

This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts and referenced statistics, contained in this presentation, including statements regarding future company strategy, operations, financial position, revenues, projected costs, plans and objectives of management, will be forward-looking statements.

All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.